Mechanisms and mitigating factors for venous thromboembolism in chronic kidney disease: the REGARDS study. J Thromb Haemost 2018; 16:
Essentials
• Chronic kidney disease (CKD) is associated with procoagulant and inflammatory biomarkers.
• We studied the association of CKD and venous thromboembolism (VTE) in a case-cohort study.
• Factor VIII, D-dimer and C-reactive protein appeared to explain the association of CKD and VTE.
• Statin use was protective against VTE in those with and without CKD.
Summary. Background: Chronic kidney disease (CKD) is associated with venous thromboembolism (VTE) risk via unknown mechanisms. Whether factors associated with reduced VTE risk in the general population might also be associated with reduced VTE risk in CKD patients is unknown. Objectives: To determine whether thrombosis biomarkers attenuate VTE risk, and whether factors associated with reduced VTE risk are similarly effective in CKD patients. Methods: Baseline biomarkers were measured in a cohort (294 VTE cases; 939 non-cases) from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, a nationwide prospective cohort study of 30 239 persons aged ≥45 years with 4.3 years of follow-up. The hazard ratio (HR) of VTE per 10 mL min À1 1.73 m
À2
decrease in estimated glomerular filtration rate (eGFR), and the percentage attenuation of this HR by each biomarker, were calculated. Associations of protective factors (physical activity, lower body mass index [BMI] , and aspirin, warfarin and statin use) with VTE were estimated in those with and without CKD. Results: The HR for VTE with lower eGFR was 1.13 (95% confidence interval [CI] 1.02-1.25), and VTE risk was attenuated by 23% (95% CI 5-100) by D-dimer, by 100% (95% CI 50-100) by factor VIII, and by 15% (95% CI 2-84) by C-reactive protein. Normal
Introduction
Kidney disease has recently emerged as a risk factor for venous thromboembolism (VTE) [1] [2] [3] [4] ; however, little is known about the mechanisms or clinical implications of this relationship. A low estimated glomerular filtration rate (eGFR) is associated with increased levels of biomarkers of inflammation and procoagulation, including higher levels of C-reactive protein (CRP), D-dimer, and factor VIII [5] [6] [7] . As these alterations are also associated with increased VTE risk [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , they might account for the relationship of kidney disease with VTE. That is, chronic kidney disease (CKD)-induced inflammation and procoagulation may explain part of the relationship between eGFR and VTE, and thus could be considered to be mediators. If this is the case, then interventions that have an impact on the biology represented by these biomarkers could lower VTE risk associated with CKD.
Epidemiological studies and clinical trials have suggested that a normal body mass index (BMI), higher physical activity [20] [21] [22] , statins [23] [24] [25] , aspirin and anticoagulants [26] [27] [28] reduce VTE risk. However, it is not known whether these factors that are protective in the general population are similarly protective in CKD patients. Knowledge of whether a particular factor is equally, or more, effective in CKD patients could also shed light on potential mechanisms of VTE in CKD patients.
In this analysis, we evaluated whether higher levels of D-dimer, FVIII and CRP attenuated the association of eGFR with VTE. We also evaluated whether established risk factors and protective medication use have similar associations with VTE risk in individuals with CKD versus those without CKD.
Methods

Study population and design
We studied participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, which is a prospective cohort study of self-reported blacks and whites in the USA, and has been previously described [29] . In brief, the REGARDS study enrolled 30 239 black and white women and men aged ≥45 years between 2003 and 2007. Exclusion criteria included medical conditions preventing long-term participation, active cancer or active treatment for cancer, residence in or awaiting placement in a nursing home, or inability to communicate in English. For this analysis, we excluded participants with missing baseline measures of kidney function (serum creatinine and cystatin C), those with prior self-reported VTE, or those receiving dialysis at baseline.
Participants were identified from a commercially available list of US residents, and recruited through postal contact followed by telephone contact. The cooperation rate was 49% of eligible participants. After completing a computer-assisted telephone interview, participants underwent an in-home visit, during which informed consent was obtained, anthropomorphic data, medication inventories and urine samples were collected, and fasting phlebotomy and an electrocardiogram were performed. Two blood pressure measurements were averaged for analysis, and blood samples were collected after a 10-12-h fast. Blood was centrifuged locally and shipped on ice packs to the University of Vermont for reprocessing and analysis or storage [30] . The study was approved by all institutional review boards at participating universities.
Event ascertainment and definitions
The primary outcome was incident VTE, consisting of deep vein thrombosis, pulmonary embolism, or both occurring together. Events were ascertained and validated as previously described [31] . In brief, VTE events were identified with four methods: review of reasons for hospitalization from telephone calls every 6 months up to February 2010; a telephone interview administered from February 2010 to February 2011 to identify any self-report of VTE from baseline to time of the call; review of all deaths by the use of periodic searches of the National Death Index, exit interviews, or records of last hospital stay; and review of medical records for other events such as stroke. For potential cases, inpatient and outpatient medical records were retrieved, and then reviewed and adjudicated by two physicians. Major disagreements were settled by a blinded third physician.
eGFR was calculated by use of the Chronic Kidney Disease Epidemiology Collaboration equation [32] on the basis of on creatinine and cystatin C [33] . Case-cohort study design
We used previously measured biomarker data for Ddimer and FVIII from a cohort random sample (CRS), selected as previously described [34] . The CRS was randomly selected within strata of race, sex and age to ensure sufficient representation of high-risk groups. To these data, we added measurements of these biomarkers in 294 VTE cases. For analyses conducted in this case-cohort sample, we excluded participants with missing laboratory data (Table S1 ). [35] .
For this VTE case-cohort study, D-dimer and FVIII were measured in 2015 in VTE cases, and the results were harmonized with measurements made previously in the CRS in 2012. The CRS D-dimer was measured in plasma with an immunoturbidometric assay on the STA-R analyzer (Diagnostica Stago, Asni eres sur Seine, France; interassay CV of 3.2-27.1%), and D-dimer for the VTE cases were run on the STA-R Evolution analyzer (Diagnostica Stago; interassay CV of 1.5-21.7%). Because analytes in cases and the cohort sample were measured at two different times, and, for D-dimer, with two different analyzers, we evaluated for analytical drift in assay results by using three approaches (Table S2) . We detected a laboratory shift in D-dimer values after the introduction of a new analyzer in 2014, which was verified in a set of experiments. No analytical drift was observed for FVIII; however, the correlation between analytes in 2012 and 2015 was weaker, which we attributed to higher analytical CVs. To harmonize results, we adjusted the D-dimer values for VTE cases down by 0.05 lg mL À1 .
Statistical analysis
In this study, we examined both the potential of mediation for selected biomarkers and effect modification by CKD status.
For the mediation analysis, we compared baseline characteristics among participants with VTE and those in the cohort sample by using chi-squared tests and t-tests as appropriate. D-dimer and CRP were highly skewed, so natural log transformation was used for the analyses. We present back-transformed (geometric) means (95% confidence interval [CI]) of log-transformed variables in the results. We used linear regression to study the cross-sectional associations of eGFR and biomarker levels (Ddimer, FVIII, and CRP). We adjusted for demographics (age, sex, race, and region of residence), and covariates that are known to be related to these biomarkers: BMI, hypertension, hyperlipidemia, diabetes, history of CVD, and smoking. Cox proportional hazards models were used to determine the hazard ratio (HR) for VTE per standard deviation (SD) increment of each biomarker. Those without an event or who died of non-VTE-related causes were censored at that time or at the time of last follow-up, whichever occurred first. We accounted for population weighting of the CRS by using the Barlow method [36] . A base model was used to adjust for age, sex, race, region, and BMI. We calculated the adjusted HR of VTE per 10-unit lower eGFR, and then added each biomarker separately to the base model. To estimate the magnitude of the potential mediation of the association of CKD with VTE by each biomarker, we calculated the percentage attenuation of the HR: percentage attenuation = 100% 9 (HR without biomarker À HR with biomarker)/(HR without biomarker À 1). The 95% CI of the percentage attenuation of the HR for eGFR and VTE was calculated by bootstrapping with replacement with 1000 replicate samples [37] . If the percentage mediation was > 100%, we reset that value to 100%. To verify that our results from the case-cohort study were representative of the full REGARDS study, we performed a sensitivity analysis by repeating the same analysis with CRP, which was measured in the entire cohort, and we present these results for qualitative comparison. We have previously reported on the competing risk for death in the association of CKD and VTE [1] .
To study effect modification by CKD status, in the full cohort we obtained risk estimates for established VTE risk factors and protective medication use from stratified Cox models with CKD as the stratification variable. We formally tested for an interaction between each protective factor and CKD by using interaction terms, which were interpreted as significant if P for interaction was < 0.10. Models were adjusted for age, sex, race, region, and BMI.
Violations of the proportional hazards assumption were tested visually and with Schoenfeld tests. For the primary predictor (eGFR), non-proportionality was further tested with an interaction term, eGFR 9 time, and HRs were estimated at various time points. For FVIII, Schoenfeld testing demonstrated significant violation of the proportional hazards assumption, but this was not confirmed with observed versus predicted plots or smoothed estimates of the log HR. All statistical analyses were performed with STATA version 14 (StataCorp. LP, College Station, TX, USA) and SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
The case-cohort sample included 1467 participants, with 386 being VTE cases. Among these, after exclusion of those with missing measures of kidney function (n = 88), those with missing measures of study biomarkers (n = 9), those receiving dialysis (n = 9), and those who reported prebaseline VTE (n = 143), there were 1233 participants in the case-cohort sample (294 VTE cases) (Table S1 ). There were 627 participants lost to follow-up in the larger cohort of 30 239 participants.
The VTE cases were more likely to be male and white than non-cases. Comorbid conditions were similar between cases and non-cases, other than BMI, which was higher in cases. eGFR was lower in VTE cases than in the cohort sample, and levels of markers of inflammation and procoagulation were higher (Table 1) .
Lower eGFR was associated with higher levels of biomarkers of inflammation and procoagulation. In the cohort sample, after adjustment for demographics and cardiovascular risk factors, each 10 (Table 4) . When all three biomarkers were included, the HR was 0.99 (95% CI 0.88-1.11). The percentage attenuations of the HRs were 23% (95% CI 5-100) for ln-D-dimer, >100% (95% CI 50-100) for FVIII, 15% (95% CI 2-84) for ln-CRP, and > 100% (95% CI 44-100) for all three biomarkers (Fig. 1) . The proportional hazards assumption may have been violated for eGFR and FVIII. Stratification of FVIII at median FVIII values demonstrated proportional hazards for VTE. There was a statistically significant interaction between eGFR and time, so we modeled the HR for VTE at 1, 3 and 5 years of follow-up. The association of eGFR and VTE decreased over time, but attenuation by FVIII was similar across follow-up time periods (Table S3) .
In a sensitivity analysis utilizing the full cohort, for each 10 mL min À1 1.73 m À2 decrease in eGFR, the ageadjusted, sex-adjusted, race-adjusted and BMI-adjusted HR of VTE was 1.09 (95% CI 1.02-1.16). After the addition of ln-CRP, the HR was 1.07 (95% CI 1.00-1.15), for a percentage attenuation of 22% (95% CI 5-69).
The associations of mitigating factors for VTE risk were assessed in the full cohort, and stratified by CKD status; the results are shown in Table 5 . Statin use was associated with a reduced VTE risk; the HR was 0.68 (95% CI 0.50-0.93) in the full cohort, and was similar in the non-CKD group; a weaker relationship was seen in the CKD group, although this difference was not statistically significant (P for interaction of statin use and CKD of 0.61). In the full cohort and in those without CKD, normal BMI was associated with an approximately 50% lower VTE risk, but there was no association in those with CKD (P for interaction of BMI and CKD of 0.07). We observed inverse associations of warfarin use and physical activity with VTE, which were similar in those with and without CKD, although the 95% CIs for these HRs included 1.0. Aspirin use was not associated with VTE risk in the full cohort, or in those with or without CKD.
Discussion
In this prospective study, the association of eGFR with VTE was attenuated by D-dimer, CRP and, in particular, FVIII. Overall, normal BMI was strongly protective against VTE, but this relationship was present only for those without CKD, and was absent in those with CKD. Statin use was associated with reduced VTE risk overall, and this association was weaker in those with CKD than in those without CKD, although this difference was not statistically significant. Warfarin use and physical activity were similarly associated with reduced VTE risk in both those with CKD and those without CKD. Baseline aspirin use was not associated with lower VTE risk in either those with CKD or those without CKD. Our findings suggest that CKD-induced activation of inflammation and procoagulation are in the causal pathway between eGFR and VTE. We confirmed prior findings that the studied biomarkers D-dimer [5, 7, 38 ] FVIII [4, 5, 7, 39] and CRP [40, 41] are more adverse with worsening kidney function (confirming our rationale for choosing them for this study). We also confirmed that D-dimer [8] , FVIII [10, 18] and CRP [14] were strongly associated with VTE. We are aware of only one prior study of mediators of the relationship between eGFR and VTE. The Multiple Environmental and Genetic Association (MEGA) casecontrol study included 2473 patients with recent VTE and 2936 matched controls in the Netherlands between 1999 and 2004, and accounted for genetic mutations and confounders such as recent surgery or immobilization [4] . Similar to the findings here, adjustment for FVIII or von Willebrand factor (VWF) measured after the VTE fully explained the association of eGFR with VTE, supporting the conclusion of both studies that FVIII and/or VWF may mediate the association of kidney function with VTE. In that study, there was no mediation by anticoagulant factors, including protein C, protein S, and antithrombin. One limitation of the MEGA study is that blood samples were collected 3 months after the VTE, so biomarker levels might have been elevated because of the recent thrombosis, and eGFR might have changed after the VTE as well. VTE may also have caused greater increases in FVIII and VWF levels in those with CKD than in those without CKD, possibly explaining the observed mediation. In our study, kidney function and biomarkers were measured at baseline, prior to the VTE, and participants with previous VTE were excluded from the analyses. Our findings confirmed the MEGA findings, reducing the likelihood that the discussed factors were important limitations in that study, and strengthening the conclusion that FVIII and/or VWF are mediators of this association. Unlike the MEGA study, we evaluated inflammation, as measured according to CRP level, and coagulation activation, as measured according to D-dimer level, as potential mediators of the association of eGFR with VTE. VTE risk was attenuated by both biomarkers, but to a lesser extent than by FVIII. An CI, confidence interval; CRP, C-reactive protein; FVIII, factor VIII; HR, hazard ratio; SD, standard deviation. Cox models were adjusted for age, sex, race, region, race 9 region, and body mass index. Ddimer and CRP were log-transformed. CI, confidence interval; CRP, C-reactive protein; FVIII, factor VIII; HR, hazard ratio; Q, quartile. eGFR as a predictor is presented as a continuous variable (HR per 10 mL minÀ1 1.73 mÀ2 decrement) and as quartiles with the reference group as the highest quartile of eGFR. Cox models were adjusted for age, sex, race, region, race 9 region, and body mass index (Base model), and for individual biomarkers. D-dimer and CRP were log-transformed.
alternative explanation for the findings of both studies is that these biomarkers are confounders but not mediators of the association of CKD with VTE. We are not aware of other studies addressing these two biomarkers. Given our finding that FVIII played a greater role in the association of eGFR with VTE than CRP or D-dimer, further discussion is warranted, specifically on the potential role of FVIII as a mediator in the association of eGFR with VTE. FVIII is a glycoprotein procofactor that is essential for coagulation. It is produced in liver sinusoidal cells and endothelial cells, and circulates bound to VWF in an inactivated form. When blood vessel injury occurs, it separates from VWF and acts a cofactor in the conversion of FIX to activated FIX. When not bound to VWF, FVIII is rapidly catabolized in the circulation via LDL receptorrelated protein, a hepatic clearance receptor whose level is reduced in kidney disease [42] [43] [44] . Our model that included all three biomarkers had similar point estimates to those of the model with just FVIII. One possible explanation for this is that inflammation as measured according to CRP level, and procoagulation as measured according to Ddimer level, exert their effects upstream, by promoting FVIII activity or by impairing FVIII degradation. Despite the potential joint mechanisms by which inflammation and procoagulation may increase VTE risk in CKD patients, FVIII appears to play a larger role. FVIII has an established role in the etiology of other CVDs [45, 46] and also in the progression of CKD [47] [48] [49] .
As CKD has only recently emerged as a risk factor for VTE, there are few data on the primary prevention of VTE in CKD patients. Here, we studied the potential for lifestyle factors and medications to reduce VTE risk in those with and without CKD by determining whether there was an interaction between CKD and a protective factor. If we found a factor that was associated with reduced VTE risk in CKD patients, it might elucidate the mechanisms of VTE in CKD patients and point to interventions that could be useful for lowering the risk. Our findings raise the hypothesis that warfarin use, statin use and higher physical activity might mitigate VTE risk in CKD patients, although a lack of power limited our interpretations in some cases, leading to CIs that included 1.0. Regarding warfarin use, we excluded those who had prior VTE, so participants presumably had different indications for warfarin, e.g. atrial fibrillation or a mechanical heart valve. The wide CIs (particularly in the CKD group) may be attributable to low numbers of events, imprecision of the predictor (i.e. baseline use not reflecting use at time of the VTE), underdosing in CKD patients (because of concerns about bleeding, and alterations in non-renal clearance), or difficulties in achieving stable International Normalized Ratios in CKD patients. Whether warfarin would be practical in the primary prevention of VTE in CKD patients would require a randomized controlled trial to determine, and the bleeding risk, which might offset any protective effect, must be taken into account [50, 51] . Our finding related to statin use confirms the results of prior studies [24, 52] , and suggests further study of statins (which do not cause bleeding) for VTE prevention in CKD patients. However, there is potential for prevalent user bias, because, in the REGARDS study, we identified prevalent medication use.
If individuals with prevalent statin use were healthier than non-users, this could account for the lower VTE risk associated with statins. In the REGARDS study, prevalent statin use may not reflect healthier participants, as participants with kidney disease were more likely to use statins than participants without kidney disease. Our finding of no association of regular aspirin use with VTE risk agrees with prior research [53] . An association of increased physical activity with lower VTE risk has been reported previously [20, 21] , and further study of its role in VTE prevention seems worthwhile. In contrast, our findings suggest that attaining a normal BMI might lower VTE risk in those without CKD, but not in those with CKD. One hypothesis to explain this is that the inflammatory and procoagulant pathways of CKD outweigh any impact that normal BMI might have in reducing VTE risk in CKD patients. Alternatively, lower BMI in CKD patients may be attributable to unmeasured confounding illness, which would mask a protective effect of lower BMI against VTE. There are several strengths of this study. This was a prospective study in which kidney function and biomarker levels were measured prior to onset of VTE, and this might better elucidate the mechanistic pathways of CKDrelated VTE risk. The study was performed in a contemporary cohort that reflects the current use of statins and trends in obesity and diabetes relevant to the US population. We had excellent representation of white and black participants, unlike many studies of VTE epidemiology. In addition, we evaluated the role of lifestyle factors in VTE risk stratified by CKD status, to attempt to develop hypotheses on how CKD patients could reduce their VTE risk.
There are limitations of this study to consider. The biomarkers were measured at baseline, which may have led to misclassification if biomarker levels changed prior to the VTE. The biomarkers in cases were measured later than in the CRS, and, in some cases, with different analyzers, but we took several steps to harmonize the data. Also, we were unable to determine whether low eGFR preceded or was the result of inflammation and procoagulation. It is possible that inflammation and procoagulation cause both CKD and VTE through independent pathways. That is, misclassification of the mediator, unknown confounding between mediator and outcome and interaction between mediator and exposure are potential limitations. We did not have information on causes of CKD, so we were unable to determine whether the mediation by inflammatory and procoagulant markers varied by CKD etiology. We demonstrated that the association of eGFR with VTE decreased with time, which may have led to underestimation of the effect size and the mediation by biomarkers. Because of blood sample processing methods in the REGARDS study, we were unable to evaluate the role of platelet function, proteins released by platelets, or VWF [30] , all of which may be other factors linking CKD with VTE. Warfarin is known to reduce VTE risk, but the association was weaker than might be expected in our study. Reasons for this could be insufficient power to detect this association, given that only 3% of the cohort reported warfarin use, or failure of baseline use to reliably indicate continuous use up to the time of VTE. Direct oral anticoagulants could not be evaluated here, owing to the time when the study was performed. Finally, although we adjusted for established VTE risk factors, there may be other factors that we did not consider that would lead to residual confounding.
Conclusion
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